|
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
This is the first report on the studies of functional VEGF polymorphisms in NPC and our preliminary data suggest that this genetic variant may play a role in mediating susceptibility to NPC, as well as, in neoplastic progression, supporting our hypothesis for VEGF involvement in NPC etiology.
|
18588866 |
2008 |
|
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Neuropilins (NRPs) are cell surface glycoproteins, acting as co-receptors for secreted Semaphorins (SEMAs) and for members of the vascular endothelial growth factor (VEGF) family; they have been initially implicated in axon guidance and angiogenesis regulation, and more recently in cancer progression.
|
31027288 |
2019 |
|
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
To investigate the role of tumor growth velocity in defining tumor progression in metastatic renal cell carcinoma patients treated with the vascular endothelial growth factor tyrosine kinase inhibitor, sorafenib.
|
30325072 |
2019 |
|
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Vascular endothelial growth factor (VEGF) expression and mutations of cancer-related genes increase with cancer progression.
|
9683299 |
1998 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Vascular endothelial growth factor (VEGF) plays a pivotal role in tumor progression via angiogenesis.
|
11589304 |
2001 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our findings indicate that OPN and VEGF were both overexpressed in the analyzed SIP tissues and were associated with clinical severity, suggesting that the OPN-VEGF axis might contribute to tumor progression by enhancing angiogenesis.
|
22186244 |
2012 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Overall, these findings highlight E2F1 and SC35 as two regulators of the VEGF(xxx)/VEGF(xxx)b angiogenic switch in human cancer cells, a role that could be crucial during tumour progression, as well as in tumour response to antiangiogenic therapies.
|
20639906 |
2010 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Vascular endothelial growth factor (VEGF) plays an important role in tumor angiogenesis and cancer progression.
|
19649652 |
2009 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Vascular endothelial growth factor (VEGF) signaling in tumor progression.
|
17324579 |
2007 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The growth of p53-deficient tumors was significantly enhanced in the presence of fibroblasts compared with that of p53-wild-type tumors or p53-deficient tumors without fibroblasts. p53-deficient cancer cells produced reactive oxygen species, which activated fibroblasts to mediate angiogenesis by secreting vascular endothelial growth factor (VEGF) both in vivo and in vitro Activated fibroblasts significantly contributed to tumor progression.
|
27520561 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Recently, ramucirumab, a drug that targets vascular endothelial growth factor receptor (VEGFR), was clinically approved; therefore, we evaluated VEGFR2 expression and its predictive roles in tumor progression in clear cell renal cell carcinoma (CCRCC).
|
31477752 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
VEGF and its receptors play a major role in physiologic and pathologic angiogenesis, which is marked in tumour progression and metastasis development.
|
30499413 |
2018 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Peripheral blood plasma or mononuclear cell isolates collected prior to therapy and at weeks 8 and 16 and at time of tumor progression were analyzed for vascular endothelial growth factor and regulatory T-cell (Treg) measurements.
|
29666297 |
2018 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
None of BIRC5, FGFR3, IGF2, KRT20, UPK2, EBF1, CDH1, FXYD3, HTERT, TP53, AGR2, HER2 and VEGF were correlated either tumour progression or survival.
|
20015323 |
2010 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Finally, we found that overexpression of hClock enhanced the expression of angiogenesis-related genes such as HIF-1α, ARNT and VEGF, and promoted epithelial-mesenchymal (-like) transition (EMT) in CRC cells, both of which are considered to be critical for tumor progression.
|
28498393 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Downregulation of miR-145 associated with cancer progression and VEGF transcriptional activation by targeting N-RAS and IRS1.
|
23201159 |
2013 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumour progression also requires angiogenesis, which is regulated by VEGF-A, itself alternatively spliced to form two families of isoforms, pro- and anti-angiogenic.
|
25010863 |
2014 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression.
|
29136509 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
It has been demonstrated that vascular endothelial growth factor (VEGF) is associated with tumor progression as an angiogenic factor in esophageal squamous cell carcinoma (SCC)s. However, the role of other angiogenic factors such as transforming growth factor-alpha (TGF-alpha), platelet-derived endothelial cell growth factor (PD-ECGF), and basic fibroblast growth factor (bFGF) are still unknown in esophageal SCCs.
|
10938383 |
2000 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Urokinase plasminogen activating system (PA system) and vascular endothelial growth factor (VEGF) were recently suggested to contribute synergistically to tumor progression.
|
12708473 |
2003 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy.
|
15897235 |
2005 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Receptor tyrosine kinases such as the epidermal growth factor receptor (EGFR, ERBB2, ERBB3, ERBB4) family, and the vascular endothelial growth factor receptor (VEGFR), play a central role in tumor progression.
|
20446891 |
2010 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Since HIF-1α has recently been implicated in PR-mediated VEGF synthesis, we undertook studies to determine whether YC-1 inhibits progestin-dependent VEGF induction and tumor progression.
|
23123638 |
2013 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Activation of receptor tyrosine kinases, such as fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and VEGF receptor (VEGFR), has been implicated in tumor progression and metastasis in human pancreatic cancer.
|
21885862 |
2011 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Vascular endothelial growth factor-A (VEGF-A) plays an important role in tumour angiogenesis and cancer progression.
|
17471570 |
2007 |